1Hatch KD. Clinical appearance andtreatment strategies for human papillomavirus: a gynecologic perspective [J]. Am J Obstet Gynecol, 1995, 172(4 Pt 2): 1340-1344.
2Jablonska S. Traditional therapies for the treatment of condylomata acuminata (genital warts)[J]. Australas J Dermatol, 1998, 39(Suppl 1): S2-4.
3Reid R, Herschman BR, Crum CP, et al. Genital warts and cervical cancer. V. The tissue basis of colposcopic change[J]. Am J Obstet Gynecol, 1984, 149(3): 293-303.
4Lascaux AS, Chosidow O. Current therapeutics in infectious dermatolo [J]. Presse Med, 2000, 29(19):1048-1052.
5Gross G, Pfister H. Role of human papillomavirus in penile cancer, penile intraepithelial squamous cell neoplasias and in genital warts [J]. Med Microbiol Immunol, 2003, 28(1):80-84.
6Boxman IL, Hogewoning A, Mulder LH, et al. Detection of human papillomavirus types 6 and 11 in pubic and perianal hair from patients with genital warts [J]. J Clin Microbiol, 1999, 37(7):2270-2273.
7von Krogh G, Dahlman-Ghozlan K, Syrianen S, et al. Potentialhuman papillomavirus reactivation following topical corticosteroid therapy of genital lichen sclerosus and erosive lichen planus [J].J Eur Acad Dermatol Venereol, 2002, 16(2):130-133.
9Goncalves MA, Burattini MN, Donadi EA, et al. Risk factors associated with genital warts in HIV-positive Brazilian women[J].Tumori, 2003, 89(1): 9-15.
10Opaneye AA. The cellular immune system in female patients with or without genital warts: a study of peripheral white blood cell components[J]. Int J STD AIDS, 1999, 10(12): 815-816.
6Fausch S C, Fahey L M, Da Silva D M, et al. Human Papillomavirus can escape immune recognition through Langerhans call phosphoinositide 3-kinase activation [J]. J Imm, 2005, 174(11): 7172.
